Acadia Pharmaceuticals, Inc. (ACAD) Tops Q3 EPS by 5c

Acadia Pharmaceuticals, Inc. (NASDAQ: ACAD) reported Q3 EPS of ($0.04), $0.05 better than the analyst estimate of ($0.09). Revenue for the quarter came in at $3.5 million versus the consensus estimate of $1.9 million.

For earnings history and earnings-related data on Acadia Pharmaceuticals, Inc. (ACAD) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
• Bernstein remains bullish on SpaceX but sees challenges in telecom ambitions
• Advance Auto Parts (AAP) PT Lowered to $43 at Truist Securities